Both in Pharmaceuticals
Arrowhead Research vs Protagonist Therapeutics
Over the past year ARWR returned +51.2% and PTGX returned +90.7%; their daily moves had a correlation of 0.32.
ARWR +51.2% PTGX +90.7%Growth of $1, one year, split-adjusted
| Metric | ARWR | PTGX |
|---|---|---|
| Price | $59.90 | $144.85 |
| Market cap | $8.46B | $9.37B |
| Today | −0.98% | +0.35% |
| 1 month | −7.5% | +4.1% |
| 6 months | −19.9% | +47.3% |
| Year to date | −9.8% | +65.8% |
| 1 year | +48.7% | +88.9% |
| Revenue growth (YoY) | +171.0% | +3749.2% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −258.2% | 76.3% |
| P/E (TTM) | — | 113.1× |
| Price / sales | 12.6× | 33.2× |
| Net cash | $737.9M | $782.6M |
| Dividend yield | — | — |
| Volatility (60d) | 45.6% | 31.3% |
| Short % of float | 8.1% | 16.8% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).